Current Molecular Medicine


Andras Guttman
University of Pannonia

Personal Subscription
Become EABM
Become Reviewer
Call for Editor

Preface promotion: free to download

Volume:3   Issue: 5
Pp: ii-ii
B. Dean
DOI: 10.2174/15665240103030500ii

Schizophrenia and Bipolar Affective Disorder: Perspectives for the Development of Therapeutics

Volume:3   Issue: 5
Pp: 393-407
S. Sundram, P. R. Joyce and M. A. Kennedy
DOI: 10.2174/1566524033479708

From Pharmacotherapy to Pathophysiology: Emerging Mechanisms of Apolipoprotein D in Psychiatric Disorders

Volume:3   Issue: 5
Pp: 408-418
E. A. Thomas, D. L. Copolov and J. G. Sutcliffe
DOI: 10.2174/1566524033479681

Muscarinic Receptors in Schizophrenia

Volume:3   Issue: 5
Pp: 419-426
B. Dean, F. P. Bymaster and E. Scarr
DOI: 10.2174/1566524033479654

The Use of Microarrays to Characterize Neuropsychiatric Disorders: Postmortem Studies of Substance Abuse and Schizophrenia

Volume:3   Issue: 5
Pp: 437-446
E. Lehrmann, T. M. Hyde, M. P. Vawter, K. G. Becker, J. E. Kleinman and W. J. Freed
DOI: 10.2174/1566524033479690

Proteomics in the Discovery of New Therapeutic Targets for Psychiatric Disease

Volume:3   Issue: 5
Pp: 447-458
Hans Voshol, Marc J. Glucksman and Jan van Oostrum
DOI: 10.2174/1566524033479645

Neurodevelopmental Animal Models of Schizophrenia: Effects on Prepulse Inhibition

Volume:3   Issue: 5
Pp: 459-471
M. Van den Buuse, B. Garner and M. Koch
DOI: 10.2174/1566524033479627

Neurodevelopment and Mood Stabilizers

Volume:3   Issue: 5
Pp: 472-482
A. J. Harwood
DOI: 10.2174/1566524033479672